TY  - JOUR
AU  - Soo, R A
AU  - Han, J-Y
AU  - Dafni, U
AU  - Cho, B C
AU  - Yeo, C M
AU  - Nadal, E
AU  - Carcereny, E
AU  - de Castro, J
AU  - Sala, M A
AU  - Bernabé, R
AU  - Coate, L
AU  - Provencio Pulla, M
AU  - Garcia Campelo, R
AU  - Cuffe, S
AU  - Hashemi, S M S
AU  - Früh, M
AU  - Massuti, B
AU  - Garcia-Sanchez, J
AU  - Dómine, M
AU  - Majem, M
AU  - Sanchez-Torres, J-M
AU  - Britschgi, C
AU  - Pless, M
AU  - Dimopoulou, G
AU  - Roschitzki-Voser, H
AU  - Ruepp, B
AU  - Rosell, R
AU  - Stahel, R A
AU  - Peters, S
AU  - ETOP 10-16 BOOSTER Collaborators
PY  - 2021
DO  - 10.1016/j.annonc.2021.11.010
UR  - http://hdl.handle.net/10668/21885
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small-cell lung cancer (NSCLC) with sensitising EGFR and acquired T790M mutations,...
LA  - en
KW  - EGFR mutations
KW  - NSCLC
KW  - bevacizumab
KW  - osimertinib
KW  - randomised controlled trial
KW  - Acrylamides
KW  - Aniline Compounds
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bevacizumab
KW  - Carcinoma, Non-Small-Cell Lung
KW  - ErbB Receptors
KW  - Humans
KW  - Lung Neoplasms
KW  - Mutation
KW  - Protein Kinase Inhibitors
TI  - A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
TY  - research article
VL  - 33
ER  -